ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 094,97
-0,09%
Dow Jones
39 069,59
0,01%
DAX
18 693,37
0,04%
Brent Oil
81,965
0,00%
Bitcoin
69 190,81
-0,11%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Alnylam Pharmaceuticals Inc (ALNY)

  7. Alnylam Pharmaceuticals Inc (ALNY) Actualités

ALNY

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALNY
DateHeureSourceTitreSymboleSociété
20/05/202422h34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
20/05/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/05/202414h00Business WireAlnylam Issues 2023 Corporate Responsibility ReportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
02/05/202414h00Business WireAlnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/04/202413h00PR Newswire (US)Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including AustraliaNASDAQ:ALNYAlnylam Pharmaceuticals Inc
18/04/202414h00Business WireAlnylam to Webcast Conference Call Discussing First Quarter 2024 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/04/202414h00Business WireAlnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled HypertensionNASDAQ:ALNYAlnylam Pharmaceuticals Inc
20/03/202413h00Business WireAlnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific SessionNASDAQ:ALNYAlnylam Pharmaceuticals Inc
13/03/202412h30Business WireAlnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive DiseaseNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202412h50Business WireAlnylam meldet positive KARDIA-2 Topline-Studienergebnisse, die eine klinisch signifikante Blutdrucksenkung bei Zugabe von Zilebesiran zu Standard-Blutdrucksenkern belegenNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202423h39Business WireAlnylam annonce des résultats positifs de l’étude KARDIA-2 démontrant des réductions cliniquement significatives de la pression artérielle lorsque le zilebesiran est ajouté à des antihypertenseurs standardsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202413h30Business WireAlnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care AntihypertensivesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
29/02/202422h00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
27/02/202414h30Business WireAlnylam to Webcast Presentations at Upcoming March Investor ConferencesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
15/02/202422h23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
15/02/202414h00Business WireAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
10/02/202400h14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
29/01/202414h00Business WireAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
09/01/202414h05Business WireAlnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s AssociationNASDAQ:ALNYAlnylam Pharmaceuticals Inc
08/01/202400h00Business WireAlnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional UpdatesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
02/01/202413h30Business WireAlnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALNYAlnylam Pharmaceuticals Inc
13/12/202313h30Business WireAlnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D DayNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/12/202314h00Business WireAlnylam to Webcast Virtual R&D DayNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/11/202314h00Business WireAlnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023NASDAQ:ALNYAlnylam Pharmaceuticals Inc
12/11/202318h08Business WireAlnylam präsentiert positive Ergebnisse der Phase-2-Dosisfindungsstudie KARDIA-1 zu Zilebesiran, einem RNAi-Prüftherapeutikum zur Behandlung von Bluthochdruck bei Patienten mit hohem kardiovaskulärem RisikoNASDAQ:ALNYAlnylam Pharmaceuticals Inc
12/11/202318h08Business WireAlnylam présente des résultats positifs de l'étude KARDIA-1 de Phase 2 de détermination de la dose évaluant zilebesiran, un traitement iARN expérimental en développement pour le traitement de l'hypertension chez les patients à risque...NASDAQ:ALNYAlnylam Pharmaceuticals Inc
11/11/202322h00Business WireAlnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular RiskNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/11/202314h00Business WireAlnylam to Webcast Presentations at Upcoming November Investor ConferencesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
02/11/202313h22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
02/11/202313h00Business WireAlnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ALNY

Dernières Valeurs Consultées

NASDAQ
AMZN
Amazon.com
NASDAQ
MSFT
Microsoft
EU
MC
Lvmh Moet Hennessy Louis...
NASDAQ
GOOGL
Alphabet
EU
CS
Axa
USI
USTECH100
US Tech 100
EU
RI
Pernod Ricard
EU
ORA
Orange
COIN
BTCUSD
Bitcoin
EU
GLE
Societe Generale
EU
VK
Vallourec
NYSE
KO
Coca Cola
NYSE
JPM
JP Morgan Chase
EU
ML
Michelin
EU
BEL20
Bel 20
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés